An empirical analysis of FDA drug shortage compounding regulations and active pharmaceutical ingredient (API) gray markets: compounding pharmacies exploited statutory shortage carve-outs to synthesize and distribute generic semaglutide and tirzepatide at $50/month, undermining Novo Nordisk's and Eli Lilly's $1,000/month monopoly list prices. cremieux.xyz